Pfizer Reports Results of Ritlecitinib in P-IIb/III Trial for the Treatment of Alopecia Areata
Shots:
- The P- IIb/III ALLEGRO trial evaluates ritlecitinib {50/30mg- (with/out one month of initial treatment with ritlecitinib- 200 mg)- 10mg- PO- qd} vs PBO in 718 patients aged ≥12yrs. with alopecia areata
- The trial met its 1EPs of improving scalp hair regrowth- patients with 30/50mg dose had ≤ 20% scalp hair loss @24wks.- the safety profile of the therapy was consistent with previous studies
- Ritlecitinib is a JAK3/TEC inhibitor & is currently being evaluated for vitiligo- RA- CD- and UC. The therapy has received BTD from the FDA to treat alopecia areata on Sept’2018
| Ref: Pfizer | Image: The Wall Street Journal
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com